.svg)
Free PSA: The Unbound Fraction of a Prostate Protease
Free PSA is the portion of prostate-specific antigen in the bloodstream that is not attached to other proteins. Prostate-specific antigen (PSA) is an enzyme made by prostate gland cells and released mainly into semen; in scientific terms it is a serine protease in the kallikrein family (kallikrein-related peptidase 3, KLK3). A small amount escapes into the blood. There, PSA exists in two states: bound to carrier proteins and unbound. The "free" test measures the unbound fraction.
PSA's biological task is to thin and liquefy semen by cutting structural proteins (proteolysis of semenogelins), which helps sperm move. In blood, PSA is not performing this job; rather, it serves as a window into prostate tissue activity and barrier integrity. Measuring free PSA focuses on the unbound pool, which reflects how PSA is released from the prostate and how much of it is sequestered by plasma inhibitors (such as alpha-1-antichymotrypsin). Free PSA testing, typically alongside total PSA, characterizes the form in which PSA circulates, providing a clearer picture of PSA biology in the circulation.
Why the Bound-Versus-Free Balance Refines Risk
Free PSA measures the portion of prostate-specific antigen circulating unbound in blood. Because prostate cells release PSA in both free and protein-bound forms, the balance between them reflects the biology of the prostate. This marker helps distinguish benign gland enlargement or irritation from more aggressive processes, guiding how concerned to be about an elevated total PSA. It is relevant only for people with a prostate.
Percent-Free Patterns: Benign Versus Concerning
Labs often report free PSA as a percentage of total PSA. In general, a higher percentage points toward benign activity, while a very low percentage suggests a higher likelihood of cancer-derived PSA. Age, prostate size, and inflammation shift this balance, so a healthy reading typically lives toward the higher end of the percentage scale when total PSA is raised.
When the free fraction is low, more PSA is bound to blood proteins. Tumors tend to secrete PSA that becomes complexed, so a low free percentage, especially alongside a raised total PSA, indicates greater cancer probability. Symptoms may be absent; when present late, they can include urinary obstruction, bone pain, or weight loss if disease spreads, reflecting effects on urinary, skeletal, and metabolic systems.
When the free fraction is high, benign prostatic hyperplasia or prostatitis is more likely. People may notice urinary frequency, weak stream, or pelvic discomfort, but systemic health is usually preserved; fertility and sexual function are typically unaffected by free PSA shifts alone.
Being in range suggests stable prostate epithelium with balanced secretion and clearance. When total PSA is only mildly elevated, a mid-to-higher percent-free pattern generally supports benign processes such as age-related enlargement rather than malignant change, aligning with preserved urinary flow and low inflammatory stress.
Recent Activity, Procedures, and Assay Limits
Interpretation depends on the accompanying total PSA; percent-free is most informative when total PSA is in a borderline screening range. Age, prostate size, recent ejaculation or procedures, infection, urinary retention, and 5-alpha-reductase therapy can shift values. Assay method and sample handling affect free PSA stability.
Pairing Free PSA With Total PSA, Exam, and Imaging
Big picture: free PSA refines what total PSA cannot, linking prostate tissue behavior to whole-body risk assessment. Interpreted with age, exam, imaging, and total PSA, it reduces unnecessary procedures and focuses attention on those at higher long-term risk of prostate cancer while recognizing common, noncancerous causes of PSA elevation.
What Free PSA Adds to the Cancer-Versus-Benign Question
This test measures the amount of prostate-specific antigen that circulates in the blood unattached to carrier proteins. PSA is made by prostate cells and enters the bloodstream with normal gland activity, growth, and irritation. The balance between free and bound PSA reflects prostate tissue architecture and inflammation, helping distinguish benign enlargement from cancer and indicating the health of the lower urinary tract and reproductive gland function.
FAQs
It measures the unbound fraction of PSA in blood and reports both absolute free PSA and the percent free PSA, helping refine risk when total PSA is raised.
Free PSA adds specificity to total PSA, clarifying whether an elevation is more likely benign or concerning, and it reduces unnecessary biopsies.
Depends on baseline total PSA, age, and risk factors. Many people repeat testing when total PSA is mildly elevated to confirm direction and stability.
Ejaculation, cycling, urinary infections, prostate size, age, recent instrumentation, and medications such as 5-alpha-reductase inhibitors or testosterone therapy.
Avoid ejaculation or vigorous cycling for 24–48 hours and avoid testing soon after prostate exams, infections, or procedures. Fasting is not required.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N., Parson, R. E., Gasior, G. H., Loveland, K. G., & Southwick, P. C. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279(19), 1542-1547. https://doi.org/10.1001/jama.279.19.1542
- US Preventive Services Task Force. (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA, 319(18), 1901-1913. https://doi.org/10.1001/jama.2018.3710
- National Cancer Institute. (2022). Prostate-specific antigen (PSA) test. https://www.cancer.gov/types/prostate/psa-fact-sheet
- Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Páez, A., Määttänen, L., Bangma, C. H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., ... Auvinen, A. (2012). Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine, 366(11), 981-990. https://doi.org/10.1056/NEJMoa1113135
- Andriole, G. L., Crawford, E. D., Grubb, R. L., 3rd, Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Clapp, J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., ... Berg, C. D. (2009). Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine, 360(13), 1310-1319. https://doi.org/10.1056/NEJMoa0810696
.avif)
.svg)
.svg)
